

Contents

| | |
|--|------|
| Contributors | xi |
| Acknowledgements | xiii |
| List of Abbreviations | xv |
| List of Icons | xix |
| Introduction | xxi |
| Part I Treatment Strategies | 1 |
| 1.01 Approaches to Positive Psychotic Symptoms | 3 |
| 1.02 Use of Plasma Levels in Antipsychotic and Mood Stabilizer Treatment | 12 |
| 1.03 Advantages of Long-Acting Injectable Antipsychotics | 16 |
| 1.04 Approach to Treatment-Resistant Schizophrenia Spectrum Patients | 22 |
| 1.05 Approach to Depressed or Suicidal Schizophrenia Spectrum Patients | 34 |
| 1.06 Approach to Persistent Aggression and Violence in Schizophrenia Spectrum Psychotic Disorders | 38 |
| 1.07 Approach to Bipolar Diathesis in Schizophrenia Spectrum Patients | 42 |
| 1.08 Approach to Anxiety in Schizophrenia Spectrum Patients | 51 |
| 1.09 Approach to Insomnia and Sleep Disturbance in Schizophrenia Spectrum Disorders | 56 |
| 1.10 Approach to Psychosis in Children and Adolescents | 60 |
| 1.11 Electroconvulsive Therapy and Other Non-Pharmacological Treatments | 80 |
| 1.12 Approach to Substance Use Disorders in Schizophrenia Spectrum Disorders | 86 |
| 1.13 Approaches to Behavioral Disturbances in Dementia and Traumatic Brain Injury Patients | 98 |

| | |
|--|-----|
| Part II Medication Reference Tables | 103 |
| First-Generation (Typical) Antipsychotics | 105 |
| 2.01 Chlorpromazine | 105 |
| 2.02 Fluphenazine | 109 |
| 2.03 Haloperidol | 113 |
| 2.04 Loxapine | 117 |
| 2.05 Perphenazine | 121 |
| 2.06 Thiothixene | 125 |
| 2.07 Trifluoperazine | 129 |
| Second-Generation (Atypical) Antipsychotics | 133 |
| 2.08 Asenapine | 133 |
| 2.09 Clozapine | 137 |
| 2.10 Iloperidone | 145 |
| 2.11 Lumateperone | 150 |
| 2.12 Lurasidone | 154 |
| 2.13 Olanzapine | 159 |
| 2.14 Paliperidone | 165 |
| 2.15 Quetiapine | 170 |
| 2.16 Risperidone | 175 |
| 2.17 Ziprasidone | 180 |
| Dopamine Partial Agonist Antipsychotics | 185 |
| 2.18 Aripiprazole | 185 |
| 2.19 Brexpiprazole | 190 |
| 2.20 Cariprazine | 195 |
| Medications for Motor/Neurologic Adverse Effects | 200 |
| 2.21 Amantadine | 200 |
| 2.22 Benztropine | 204 |
| 2.23 Diphenhydramine | 208 |
| 2.24 Trihexyphenidyl | 213 |
| Mood Stabilizers | 217 |
| 2.25 Carbamazepine | 217 |
| 2.26 Lamotrigine | 222 |
| 2.27 Lithium | 228 |
| 2.28 Valproic Acid | 233 |
| Selective Serotonin Reuptake Inhibitor Antidepressants | 238 |
| 2.29 Citalopram | 238 |
| 2.30 Escitalopram | 242 |

| | | |
|------|--|-----|
| 2.31 | Fluoxetine | 246 |
| 2.32 | Fluvoxamine | 251 |
| 2.33 | Paroxetine | 256 |
| 2.34 | Sertraline | 261 |
| | SSRI/5HT _{1A} Partial Agonist Antidepressants | 265 |
| 2.35 | Vilazodone | 265 |
| 2.36 | Vortioxetine | 269 |
| | Serotonin/Norepinephrine Reuptake Inhibitor Antidepressants | 273 |
| 2.37 | Desvenlafaxine | 273 |
| 2.38 | Duloxetine | 277 |
| 2.39 | Levomilnacipran | 282 |
| 2.40 | Venlafaxine | 286 |
| | Mixed Mechanism Antidepressants | 290 |
| 2.41 | Bupropion | 290 |
| 2.42 | Mirtazapine | 295 |
| 2.43 | Trazodone | 299 |
| | Tricyclic Antidepressants | 304 |
| 2.44 | Amitriptyline | 304 |
| 2.45 | Clomipramine | 308 |
| 2.46 | Desipramine | 312 |
| 2.47 | Doxepin | 316 |
| 2.48 | Imipramine | 320 |
| 2.49 | Nortriptyline | 324 |
| | Monoamine Oxidase Inhibitor Antidepressants | 328 |
| 2.50 | Isocarboxazid | 328 |
| 2.51 | Moclobemide | 331 |
| 2.52 | Phenelzine | 335 |
| 2.53 | Transdermal Selegiline | 338 |
| 2.54 | Tranylcypromine | 342 |
| | Anxiolytics | 345 |
| 2.55 | Alprazolam | 345 |
| 2.56 | Buspirone | 350 |
| 2.57 | Clonazepam | 354 |
| 2.58 | Diazepam | 358 |
| 2.59 | Hydroxyzine | 362 |
| 2.60 | Lorazepam | 365 |

| | |
|--|-----|
| Sedatives | 370 |
| 2.61 Diphenhydramine | 370 |
| 2.62 Eszopiclone | 371 |
| 2.63 Hydroxyzine | 375 |
| 2.64 Lorazepam | 376 |
| 2.65 Oxazepam | 377 |
| 2.66 Temazepam | 381 |
| 2.67 Zaleplon | 385 |
| 2.68 Zolpidem | 389 |
| Circadian Regulators | 393 |
| 2.69 Melatonin | 393 |
| 2.70 Ramelteon | 397 |
| 2.71 Tasimelteon | 401 |
| Stimulants | 404 |
| 2.72 Atomoxetine | 404 |
| 2.73 Dextroamphetamine | 408 |
| 2.74 Lisdexamfetamine | 415 |
| 2.75 Methylphenidate | 421 |
| 2.76 Mixed Amphetamine Salts | 427 |
| Histaminic Stimulants | 434 |
| 2.77 Armodafinil | 434 |
| 2.78 Modafinil | 440 |
| Cognitive Agents | 446 |
| 2.79 Dextromethorphan/Quinidine | 446 |
| 2.80 Donepezil | 452 |
| 2.81 Galantamine | 458 |
| 2.82 Memantine | 465 |
| 2.83 Rivastigmine | 469 |
| α_2 -Adrenergic Agonists | 476 |
| 2.84 Clonidine | 476 |
| 2.85 Guanfacine | 482 |
| Appendices | 487 |
| 3.01 Optimal Antipsychotic Plasma Concentration Ranges | 489 |
| 3.02 Optimal Mood Stabilizer Plasma Concentration Ranges | 490 |

| | | |
|------|---|-----|
| 3.03 | Formulas for Correcting QT Interval | 491 |
| 3.04 | Common Cytochrome P450 Inducers and Inhibitors | 492 |
| 3.05 | Management of Constipation | 493 |
| 3.06 | Child-Pugh Hepatic Function Scoring | 495 |
| 3.07 | Loading of Lithium and Valproic Acid | 496 |
| 3.08 | Treatment of Prolactin Elevation | 497 |
| 3.09 | A Select List of Foods High in Tyramine | 499 |
| 3.10 | Medications That Present Risk for Serotonin Syndrome When Combined with Monoamine Oxidase Inhibitor | 501 |
| 3.11 | Selected Treatment of Psychomotor Agitation Algorithm | 502 |
| | Index | 508 |